论文部分内容阅读
为探讨表现为原发性肾病综合征 (PNS)的系膜增生性肾小球肾炎(MsPGN)治疗、疗效和预后 ,将106例PNS患儿按临床分为单纯型和肾炎型两组。按病理分为单纯MsPGN和非单纯MsPGN(MsPGN伴局灶性节段肾小球硬化或/和肾小管间质病变 ) ,并对临床和病理资料进行分析和总结。结果表明 ,72例经泼尼松8周治疗后获缓解 ;单纯型和肾炎型肾病两组之间泼尼松完全效应无明显差异 (χ2=1.19,P>0.05) ,单纯MsPGN组完全效应明显高于非单纯MsPGN组 (χ2=25.6,P<0.01) ,辅以环磷酰胺冲击治疗 (CTX_PT)可提高疗效 ,提示临床分型有其局限性。MsPGN若合并局灶节段肾小球硬化或/和肾小管间质病变者预后不容乐观。
To explore the treatment, efficacy and prognosis of mesangial proliferative glomerulonephritis (MsPGN) manifested as primary nephrotic syndrome (PNS), 106 cases of PNS were divided into two groups according to their clinical characteristics: simple type and nephritis type. According to the pathology is divided into simple MsPGN and non-simple MsPGN (MsPGN with focal segmental glomerular sclerosis and / and tubulointerstitial lesions), and clinical and pathological data were analyzed and summarized. The results showed that 72 patients were relieved after 8 weeks of prednisone treatment. There was no significant difference in the complete effect of prednisone between the two groups (χ2 = 1.19, P> 0.05). The complete effect of MsPGN alone group was obvious Higher than non-MsPGN group (χ2 = 25.6, P <0.01), supplemented with cyclophosphamide shock therapy (CTX_PT) can improve the efficacy, suggesting that the clinical classification has its limitations. MsPGN if combined with focal segmental glomerulosclerosis and / or tubulointerstitial disease prognosis is not optimistic.